The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Behavioral Intervention and Anti-Obesity Drug Therapy

비만의 행동중재와 약물치료

  • Kim, Mee Kyoung (Department of Internal Medicine, The Catholic University of Korea College of Medicine)
  • 김미경 (가톨릭대학교 의과대학 내과학교실)
  • Published : 2013.05.01
⟨ Previous Next ⟩

Abstract

Obesity is associated with a reduction in life expectancy and an increase in mortality from cardiovascular diseases, cancer, and other causes. The U.S. Preventive Service Task Force (USPSTF) recommends screening all adults for obesity. Clinicians should offer or refer patients with a body mass index of $30kg/m^2$ or higher to intensive, multicomponent behavioral interventions. Behavioral interventions can lead to a moderate weight loss and improvement in blood sugar and other risk factors for cardiovascular disease. Behavioral interventions decreased the incidence of diabetes diagnosis by about 50% over 2 to 3 years. Orlistat, phentermine, diethylpropion, phendimetrazine, mazindol have been approved as anti-obesity drugs by Korea Food and Drug Administration. The U.S. Food and Drug Administration approved lorcaserin and phentermine plus topiramate combination for treatment of obesity in 2012.

Keywords

References

  1. James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010;363:905-917. https://doi.org/10.1056/NEJMoa1003114
  2. Moyer VA; U.S. Preventive Services Task Force. Screening for and management of obesity in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012;157:373-378.
  3. Ryan DH, Johnson WD, Myers VH, et al. Nonsurgical weight loss for extreme obesity in primary care settings: results of the Louisiana Obese Subjects Study. Arch Intern Med 2010;170:146-154. https://doi.org/10.1001/archinternmed.2009.508
  4. Unick JL, Beavers D, Bond DS, et al. The long-term effectiveness of a lifestyle intervention in severely obese individuals. Am J Med 2013;126:236-242. e1-2. https://doi.org/10.1016/j.amjmed.2012.10.010
  5. Li G, Zhang P, Wang J, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 2008;371:1783-1789. https://doi.org/10.1016/S0140-6736(08)60766-7
  6. Deedwania PC. Risk of diabetes and cardiovascular disease: best to return back to the basics: comment on "Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus". Arch Intern Med 2010;170:1575-1577.
  7. Kim KS, Park SW. Drug therapy for obesity. Korean J Obes 2012;21:197-202. https://doi.org/10.7570/kjo.2012.21.4.197
  8. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155-161. https://doi.org/10.2337/diacare.27.1.155
  9. Ahmed MH. Orlistat and calcium oxalate crystalluria: an association that needs consideration. Ren Fail 2010;32: 1019-1021. https://doi.org/10.3109/0886022X.2010.501929
  10. Kang JG, Park CY, Kang JH, Park YW, Park SW. Randomized controlled trial to investigate the effects of a newly developed formulation of phentermine diffuse-controlled release for obesity. Diabetes Obes Metab 2010;12:876-882. https://doi.org/10.1111/j.1463-1326.2010.01242.x
  11. Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM Trial. J Clin Endocrinol Metab 2011;96:3067-3077. https://doi.org/10.1210/jc.2011-1256
  12. Kushner RF. Pharmacologic management of obesity. Pediatr Blood Cancer 2012;58:140-143. https://doi.org/10.1002/pbc.23366
  13. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:1341-1352. https://doi.org/10.1016/S0140-6736(11)60205-5
  14. Apovian C, Aronne L, Rubino D, et al. A randomized, phase 3Trial of naltrexone SR/Bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring) 2013 Feb 14 [Epub]. http://dx.doi.org/10.1002/oby.20309.

Cited by

  1. 주관적 체형인식이 체중조절방법 선택에 미치는 영향: 2012년 국민건강영양조사 자료를 이용하여 vol.14, pp.1, 2014, https://doi.org/10.15429/jkomor.2014.14.1.29
  2. 구절초 추출물의 항비만 활성 vol.25, pp.3, 2013, https://doi.org/10.5352/jls.2015.25.3.299
  3. 비만증에 대한 부항요법의 중의학 임상연구 고찰 vol.15, pp.2, 2015, https://doi.org/10.15429/jkomor.2015.15.2.137
  4. 체질 량 지수가 정상인 여성의 주관적 체형 인식이 체중변화에 미치는 영향 vol.9, pp.4, 2018, https://doi.org/10.15207/jkcs.2018.9.4.313
  5. The Effects of Weight Control Behaviors among Korean Obese Adults vol.39, pp.4, 2018, https://doi.org/10.4082/kjfm.17.0021